Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Martine Gehin, Robert F. Storey, Corine Bernaud & Jasper Dingemanse. (2023) Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction. Expert Opinion on Drug Metabolism & Toxicology 19:10, pages 697-708.
Read now
Read now
Nariman Shahid, Alia Erum, Muhammad Zaman, Ume Ruqia Tulain, Qurat-ul-ain Shoaib, Nadia Shamshad Malik, Rizwana Kausar, Ayesha Rashid & Umaira Rehman. (2022) Synthesis and evaluation of chitosan based controlled release nanoparticles for the delivery of ticagrelor. Designed Monomers and Polymers 25:1, pages 55-63.
Read now
Read now
Nariman Shahid, Alia Erum, Muhammad Zaman, Ume Ruqia Tulain, Qurat-ul-ain Shoaib, Abdul Majeed, Muhammad F Rasool, Imran Imran, Sultan Alshehri, Behnam Noorani & Faleh Alqahtani. (2021) pH-Responsive Nanocomposite Based Hydrogels for the Controlled Delivery of Ticagrelor; In Vitro and In Vivo Approaches. International Journal of Nanomedicine 16, pages 6345-6366.
Read now
Read now
Articles from other publishers (16)
Christer Tannergren, Harshad Jadhav, Emma Eckernäs, Jonas Fagerberg, Patrick Augustijns & Erik Sjögren. (2023) Physiologically based biopharmaceutics modeling of regional and colon absorption in humans. European Journal of Pharmaceutics and Biopharmaceutics 186, pages 144-159.
Crossref
Crossref
Ambuj DubeyMrMr, Bhavna A. PatelDr.Dr. & Shraddha J. ParmarDr.Dr.. (2023) Combined novel approach to enhance the solubility and Intestinal absorption: A recent review. EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES.
Crossref
Crossref
James M. Butler. 2022. Oral Drug Delivery for Modified Release Formulations. Oral Drug Delivery for Modified Release Formulations
103
117
.
Nariman Shahid, Alia Erum, Muhammad Zaman, Muhammad Omer Iqbal, Romana Riaz, Ruqia Tulain, Tousif Hussain, Muhammad W Amjad, Maria AG Raja, Umer Farooq & Waqar Aman. (2022) Fabrication of thiolated chitosan based biodegradable nanoparticles of ticagrelor and their pharmacokinetics. Polymers and Polymer Composites 30, pages 096739112211087.
Crossref
Crossref
Bret BernerPeter Scholes, Vanessa Zann, Wu Lin, Chris Roe & Bret Berner. 2021. Drug Delivery Approaches. Drug Delivery Approaches
99
219
.
Katarzyna Buszko, Krystian Kubica, Eva-Luise Hobl, Piotr Adamski, Kacper Wnuk, Bernd Jilma & Jacek Kubica. (2021) Pharmacokinetic Modeling of Morphine’s Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers. Frontiers in Physiology 12.
Crossref
Crossref
Nafiseh Hosseini‐Ashtiani & Azadeh Tadjarodi. (2021) Design and Characterization of Ticagrelor‐Loaded Chitosan Biopolymer to Improve Chemical and Biological Properties of the Drug. ChemistrySelect 6:8, pages 1741-1747.
Crossref
Crossref
Shuaibing Liu, Ziteng Wang, Lei Hou, Xin Tian, Xiaojian Zhang & Weimin Cai. (2020) Predicting the effect of tea polyphenols on ticagrelor by incorporating transporter-enzyme interplay mechanism. Chemico-Biological Interactions 330, pages 109228.
Crossref
Crossref
Ahmed Hassen Elshafeey, Reham Zayed, Marwa Hassan Shukr & Ibrahim Elsayed. (2020) Sucrose acetate isobutyrate based nanovesicles: A promising platform for drug delivery and bioavailability enhancement. Journal of Drug Delivery Science and Technology 58, pages 101806.
Crossref
Crossref
Uta Schilling, Jasper Dingemanse & Mike Ufer. (2020) Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists. Clinical Pharmacokinetics 59:5, pages 545-566.
Crossref
Crossref
Min Zhang, Xiang You, Meng Ke, Zheng Jiao, Hongwei Wu, Pinfang Huang & Cuihong Lin. (2019) Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics. Journal of Pharmaceutical Sciences 108:8, pages 2781-2790.
Crossref
Crossref
Hasseri Halim, Decha Pinkaew, Preedakorn Chunhacha, Patuma Sinthujaroen, Perumal Thiagarajan & Ken Fujise. (2019) Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel. PLOS ONE 14:6, pages e0218934.
Crossref
Crossref
Gi-Ho Son, Young-Guk Na, Hyun Wook Huh, Miao Wang, Min-Ki Kim, Min-Gu Han, Jin-Ju Byeon, Hong-Ki Lee & Cheong-Weon Cho. (2019) Systemic Design and Evaluation of Ticagrelor-Loaded Nanostructured Lipid Carriers for Enhancing Bioavailability and Antiplatelet Activity. Pharmaceutics 11:5, pages 222.
Crossref
Crossref
Xiaogang Liu, Ye Gu, Yufeng Liu, Mingjing Zhang, Yuting Wang & Liqun Hu. (2018) Ticagrelor attenuates myocardial ischaemia-reperfusion injury possibly through downregulating galectin-3 expression in the infarct area of rats. British Journal of Clinical Pharmacology 84:6, pages 1180-1186.
Crossref
Crossref
Khalil Ibrahim, Rakesh R. Goli, Rohan Shah, Jon R. Resar, Steven P. Schulman & John W. McEvoy. (2018) Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: Design, rationale, and sample characteristics of the PACIFY randomized trial. Contemporary Clinical Trials 64, pages 8-12.
Crossref
Crossref
Renli Teng. (2015) Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clinical Pharmacokinetics 54:11, pages 1125-1138.
Crossref
Crossref